Highlights from the 9th Microbiome R&D and Business Collaboration Forum – Europe
Posted 10th January 2022 by Nicholas Noakes
It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.
Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology
Posted 30th September 2021 by Nicholas Noakes
“What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.“
Dr Hamid Tizhoosh
A Paradigm Change in Skin Health
Posted 7th September 2021 by Nicholas Noakes
There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.
Conversation with one of the founders of modern digital pathology
Posted 31st August 2021 by Nicholas Noakes
“Digital pathology has reached the point where if you don’t have digitized slides, you will not be able to do six out of ten things that other pathologists can do today.”
Dr. Anil Parwani
Drug Development for NASH with Fibrosis: Expedited Programs
Posted 30th July 2021 by Nicholas Noakes
George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.
Gut dysbiosis in clinical Huntington’s Disease
Posted 22nd July 2021 by Nicholas Noakes
Speaking at the recent Microbiome R&D and Business Collaboration Forum, Anthony Hannan explored research using mouse models for brain disorders, particularly in Huntington’s disease (HD), schizophrenia, depression, and anxiety disorders. He also examined the role of gene-environment interactions involving mental activity, physical activity, stressors, and diet.
Circulating biomarkers in melanoma immunotherapy
Posted 29th June 2021 by Nicholas Noakes
Genevieve Boland, speaking at the Research & Technology Series, described the translational research conducted at her laboratory. Using tumour and blood samples from patients before treatment, at meaningful clinical changes, progression, and post-mortem she, and her team are trying to understand the biology of Melanoma to treat patients better.
Guidelines for Validating Whole Slide Imaging for Diagnostic Purposes
Posted 25th May 2021 by Nicholas Noakes
Andrew Evans, speaking at the Digital Pathology & AI Congress USA, described new guidelines he helped to draft for validating whole-slide-imaging for diagnostic purposes. First published in 2013 the guidelines were designed to address the fundamental question, “what needs to be done to validate a whole slide imaging for diagnostic use?”. The review producing the new guidelines was published in May 2021.
